Genetic Technologies Limited Stock price

Equities

GTG

AU000000GTG7

Healthcare Facilities & Services

Market Closed - Australian S.E. 12:59:28 2024-03-28 am EDT 5-day change 1st Jan Change
0.14 AUD +12.00% Intraday chart for Genetic Technologies Limited 0.00% +3.70%
Sales 2024 * - Sales 2025 * - Capitalization 16.16M 24.82M
Net income 2024 * -4M -6.14M Net income 2025 * - 0 EV / Sales 2024 * -
Net cash position 2024 * 2.9M 4.45M Net cash position 2025 * 2.5M 3.84M EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.17%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Genetic Technologies Limited

1 day+12.00%
Current month+16.67%
1 month+16.67%
6 months-44.00%
Current year+3.70%
More quotes
1 week
0.13
Extreme 0.125
0.19
1 month
0.10
Extreme 0.1
0.19
Current year
0.09
Extreme 0.093
0.19
1 year
0.09
Extreme 0.093
0.40
3 years
0.09
Extreme 0.093
1.10
5 years
0.09
Extreme 0.093
1.40
10 years
0.09
Extreme 0.093
9.10
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-01-31
Chief Tech/Sci/R&D Officer - 15-12-31
Director/Board Member - 18-01-30
Members of the board TitleAgeSince
Director/Board Member 65 14-09-23
Chairman - 18-01-30
Director/Board Member - 18-01-30
More insiders
Date Price Change Volume
24-03-28 0.14 +12.00% 7 391
24-03-27 0.125 -10.71% 38,303
24-03-26 0.14 +3.70% 12,083
24-03-25 0.135 0.00% 50,547
24-03-22 0.135 -3.57% 517,936

Delayed Quote Australian S.E., March 28, 2024 at 12:59 am EDT

More quotes
Genetic Technologies Limited (GTG) is an Australia-based molecular diagnostics company. The Company offers predictive genetic testing and risk assessment tools. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its GeneType and EasyDNA brands. The Company operates through three segments: EasyDNA, AffinityDNA, and geneType / Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. The geneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. GeneType also offers integrated risk testing for a range of serious conditions. EasyDNA and AffinityDNA offer deoxyribonucleic acid (DNA) testing services.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Genetic Technologies Limited - Australian S.E.